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Abstract
Background: Exercise is beneficial for blood glucose metabolism. However, whether moderate aerobic exercise
could improve impaired fasting glucose is unknown. And the mechanism is also needed to investigate.
Methods: A cross-sectional research was performed and 120 participants with impaired fasting glucose (IFG) were
randomly assigned into active and controlled groups. Briefly, participants in active group were required to take
moderate aerobic exercise at least 30 min for five times per week, whereas in controlled group, participants were
also advised to take exercise but not mandatorily required the same degree as that of active group. At baseline and
3 month’s follow-up, laboratory and demographic variables were compared.
Results: At baseline, no significant between-group differences were observed. Generally, leukocyte ROCK2 activity
in the active and controlled groups were 58.7 ± 6.0 mg/mL and 60.2 ± 7.3 mg/mL, and daily average exercise time
at baseline in both groups was extremely little, with 5.2 ± 3.8 min and 5.9 ± 3.5 min, respectively. After 3 months’
follow-up, 52 and 56 participants in the active and controlled groups completed the whole program. Compared to
baseline, leukocyte ROCK2 activity and daily average exercise time were improved in both groups. Nonetheless,
compared to the controlled group, leukocyte ROCK2 activity was reduced more profoundly and the daily average
exercise time was longer in the active group (37.5 ± 6.3 min versus 18.3 ± 7.2 min, p < 0.05). Moreover, the
percentage of IFG in the active group was decreased more prominently than the controlled group (76.9 % versus
82.1 %, p < 0.05). Multivariate regression analyses revealed that exercise time and leukocyte ROCK2 activity was
significantly associated with IFG, with OR of 0.836 (active group versus controlled group, 95 % CI 0.825-0.852, p <
0.05) in exercise time, and 1.043 (controlled group versus active group, 95 % CI 1.021–1.069, p < 0.05) in leukocyte
ROCK2 activity. In addition, exercise time was significantly associated with leukocyte ROCK2 activity, with OR of
0.822 (active group versus controlled group, 95 % CI 0.818–0.843, p < 0.05).
Conclusion: In subjects with IFG, increased daily average exercise time is beneficial for improving fasting blood
glucose metabolism, and the mechanism may be associated with its effects on attenuating leukocyte ROCK2
activity.
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Introduction
Currently, diabetes mellitus (DM) has become one of
the most important risk factors for cardiovascular dis-
ease in both developed and developing countries [1].
Previously, some studies revealed that improving glucose
metabolism by medicines could reduce adverse out-
comes in subjects with coronary artery diseases [2, 3]. In
addition, emerging evidence reveals that compared to
the controlled participants, the incidences of ASCVD
(mainly including ischemic stroke, coronary artery dis-
ease and peripheral artery disease) and DM in popula-
tions with pre-diabetic status such as impaired fasting
glucose (IFG) are also profoundly increased [4–6].
Therefore, effectively and efficiently treating this sub-
group of pre-diabetic population is clinical relevance to
reduce the incident DM and ASCVD. Knowingly, glu-
cose metabolism disorder contributes to the develop-
ment and progression of atherosclerosis in patients with
DM. For example, increased serum glucose level leads to
endothelial dysfunction and thereby causes leukocytes
infiltration and accumulation in vascular wall [7, 8]. In
addition, hyperglycemia contributes to increased platelet
activity which is positively associated with atheroscler-
otic plaque formation and progression [9].
ROCKs are important regulators of cellular apoptosis,
proliferation, metabolism, and migration via control of
the actin cytoskeletal assembly [10]. In the past decades,
ROCKs have been identified associated with endothelial
dysfunction, platelet activation, inflammatory reaction
and oxidative stress, macrophages proliferation and
endothelial apoptosis, and smooth muscle cells contrac-
tion in experimental researches [10–14]. Moreover, in-
creased ROCK activity contributes to atherosclerosis
progression and inhibiting ROCK activity by its inhibitor
fasudil is beneficial for improving symptoms and clinical
outcomes in patients with ASCVD [15, 16]. Knowingly,
increased ROCK activity is associated with metabolic
syndrome development [17] and lifestyle modification
such as moderate aerobic exercise is helpful to improve
metabolic disorder [18]. However, whether moderate
aerobic exercise is beneficial for attenuating ROCK ac-
tivity needs further investigation. Thus this, we con-
ducted a cross-sectional clinical research to address
these questions. Hopefully, results from our preliminary




Totally, 120 participants who were diagnosed as IFG ac-
cording to the criterion of guideline recommendation
were enrolled [1]. All participants were without previous
myocardial infarction, ischemic stroke, peripheral artery
disease, severe liver and renal dysfunction, and anemia.
Oral informed consent was obtained before enrollment.
At baseline, all enrolled participants were randomly
assigned into the active group and controlled group. Par-
ticipants in the active group were recommended to man-
datorily take at least 30 min of moderate aerobic
exercise (jogging or brisk walking) at least 5 days per
week. Briefly, watch or the time facility in the mobile-
phone was used to record the duration of moderate aer-
obic exercise which was recorded on a paper. Similarly,
participants in the controlled group were also advised to
take exercise but were not mandatorily required to take
the same degree of exercise as that in the active group.
In terms of mandatory requirement, which meant that
members of our research group called participants in
the active group every 3 days by telephone to check out
and encourage them to follow protocol’s instructions.
However, participants in the controlled group would not
get such kind of motivated encouragement. After
3 months’ follow-up, parameters of interest collected
and compared between these two groups.
Blood parameters measurement
At baseline and 3 months’ follow-up, fasting blood sam-
ples were drawn for the measurements of serological pa-
rameters including lipid profiles, liver and renal
functions, high-sensitivity C-reactive protein (Hs-CRP),
fasting blood glucose (FBG), fasting C-peptide and insu-
lin levels, and glycated hemoglobin level (HbA1c). All
the measurements were conducted in the laboratory
center of our hospital.
Demographic data collection
Demographic data including age, gender, smoking status,
body mass index (BMI), waist circumference, systolic
and diastolic blood pressure (SBP and DBP), heart rate,
hypertension and dyslipidemia, daily average exercise
time, current medicine usage were collected by two
working staffs.
Cytoplasm level of ROCK2 activity assessment
Fasting venous blood was drawn and leukocyte was iso-
lated. The cytoplasm of leukocyte was obtained and
stored at −80 °C until use. Cytoplasm level of ROCK2
activity was assessed by enzyme-linked immune-sorbent
assay (ELISA kit, abcam company, ab160505). Briefly, at
baseline and 3 months’ follow-up, fasting blood samples
were drawn and centrifuged at 1200 g for 5 min, and
then the cytoplasm of leukocyte was obtained and stored
at −80 °C until use. All the procedures were according
to the manufactures’ instruction. Optical density of each
sample was detected by enzyme-labeling measuring in-
strument at a wavelength of 460 nm, and the activity
was figured out on the standard curve. All the
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measurements were repeated for 3 times to figure out
the arithmetic average.
Statistical analysis
Continuous data was presented as mean ± SD or median
(inter-quartile range) as appropriate, and was compared
by the Student’s t-test when data was normally distrib-
uted, otherwise was compared by the Wilcoxon rank-
sum test. Categorical data was presented as percentage
and was compared by χ2 test. Multivariate regression
analysis was conducted to evaluate the relationship be-
tween exercise and other variables with the ROCK2 ac-
tivity and IFG incidence, respectively. All reported p
values were 2-sided, and a p value of < 0.05 was consid-
ered statistically significant. All statistical analyses were
conducted with the SPSS statistical package for Win-
dows version 19.0 (SPSS Inc., Chicago, Illinois).
Results
Baseline characteristics of the active and controlled
groups
Baseline characteristics of the active and controlled
groups were evaluated and compared, and no significant
between-group differences of these variables were ob-
served (Table 1). Generally, male participant is predom-
inant in present research. The BMI were 24.6 ± 3.3 kg/
m2 and 24.8 ± 3.7 kg/m2, respectively, and nearly 31.7 %
and 33.3 % of participants were overweight and obese.
The percentages of participants with smoking (38.3 %
versus 35.0 %), hypertension (26.7 % versus 30.0 %), and
dyslipidemia (31.7 % versus 30.0 %) were comparable.
Serum level of FBG, HbA1c and other serological indices
were also no significant different. Serum levels of Hs-
CRP were comparably increased in the active and con-
trolled groups. Leukocyte cytoplasm ROCK2 activity in
the active and controlled groups were 58.7 ± 6.0 mg/mL
and 60.2 ± 7.3 mg/mL, respectively. Fasting C-peptide
and insulin levels in both groups were below the normal
lower limit and without significant difference between
groups. Daily average exercise time at baseline in both
groups was extremely little, with 5.2 ± 3.8 min and 5.9 ±
3.5 min, respectively. Current medicines usage for anti-
platelet, hypertension and dyslipidemia were similar in
both groups, and no medicine used for hyperglycemia
was reported.
Variable comparison between groups after 3 months’
follow-up
After 3 months’ follow-up, six participants in the active
group were dropout due to be unable to complete pre-
set exercise program and two participants moved to
other cities, and four participants in the controlled
group were dropout due to move to other cities. Vari-
ables between groups were compared. As presented in
Table 2, importantly, variables including BMI, waist cir-
cumference, and the percentages of obese and smoking
were all comparably reduced in both groups compared
to baseline (p < 0.05 for all comparisons). In addition,
compared to baseline, the serological indices including
lipid profiles, FBG, Hs-CRP, fasting C-peptide and insu-
lin levels, and ROCK2 activity were improved in both
groups. Nonetheless, after 3 months’ follow-up, com-
pared to the controlled group, the percentage of
Table 1 Baseline characteristics of the active and controlled
groups
Variables Active (n = 60) Controlled (n = 60)
Age (years) 42.4 ± 5.8 44.1 ± 6.6
Male, n (%) 33 (55.0) 35 (58.3)
BMI (kg/m2) 24.6 ± 3.3 24.8 ± 3.7
Overweight, n (%) 10 (16.7) 12 (20.0)
Obese, n (%) 9 (15.0) 8 (13.3)
Waist circumference (cm) 84.4 ± 7.6 82.9 ± 8.3
Smoking, n (%) 23 (38.3) 21 (35.0)
Hypertension, n (%) 16 (26.7) 18 (30.0)
Dyslipidemia, n (%) 19 (31.7) 18 (30.0)
SBP (mmHg) 127.8 ± 16.4 125.9 ± 15.7
DBP (mmHg) 79.8 ± 10.6 78.5 ± 11.7
HR (bpm) 73.7 ± 10.4 76.5 ± 9.9
TG (mmol/L) 1.8 ± 0.4 1.9 ± 0.3
TC (mmol/L) 5.7 ± 0.6 5.8 ± 0.5
LDL-C (mmol/L) 3.6 ± 0.3 3.7 ± 0.4
HDL-C (mmol/L) 1.1 ± 0.3 1.1 ± 0.2
Lp(a) (mg/L) 132.4 ± 15.6 135.7 ± 17.3
FBG (mmol/L) 6.3 ± 0.5 6.4 ± 0.4
HbA1c (%) 5.6 ± 0.4 5.6 ± 0.5
Cr (μmol/L) 98.7 ± 10.6 99.2 ± 9.9
BUN (mmol/L) 5.6 ± 1.3 5.9 ± 1.4
Hs-CRP (mg/L) 5.2 ± 1.1 5.6 ± 1.0
ROCK2 activity (mg/mL) 58.7 ± 6.0 60.2 ± 7.3
Fasting C-peptide level (nmol/L) 0.26 ± 0.05 0.28 ± 0.07
Fasting insulin level (pmol/L) 13.6 ± 2.2 14.1 ± 2.8
Daily average exercise time (min) 5.2 ± 3.8 5.9 ± 3.5
Aspirin, n (%) 28 (46.7) 26 (43.3)
ACEI, n (%) 9 (15.0) 7 (11.7)
ARB, n (%) 4 (6.7) 5 (8.3)
CCB, n (%) 4 (6.7) 3 (5.0)
Statins, n (%) 14 (23.3) 13 (21.7)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, HR heart rate (beat per minute), TG triglyceride, TC total cholesterol,
LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein
cholesterol, Lp(a) lipoprotein (a), FBG fasting blood glucose, Cr creatinine,
BUN blood urea nitrogen, ACEI angiotensin converting enzyme inhibitor,
ARB angiotensin receptor blocker, CCB calcium channel blocker
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overweight, serum levels of Lp(a) and Hs-CRP, and
ROCK2 activity were reduced more profoundly in the
active group (p < 0.05), and the increments of fasting C-
peptide and insulin levels were more prominent in the
active group (p < 0.05). The percentages of medicine
usage including anti-platelet, anti-hypertension and sta-
tins were similarly increased in both groups. Notably,
the daily average exercise time in both groups were sig-
nificantly increased compared to baseline. However,
compared to the controlled group, the exercise time in
the active group was significantly longer (37.5 ± 6.3 min
versus 18.3 ± 7.2 min, p < 0.05). Briefly, 48 participants
(92.3 %) in the active group and seven participants
(12.5 %) in the controlled group completed the exercise
program during these 3 months follow-up. Moreover,
the percentage of IFG in the active group was also sig-
nificantly decreased than that in the controlled group
(76.9 % versus 82.1 %, p < 0.05).
Relationship between exercise and other variables with
IFG
Multivariate regression analyses were performed to
evaluate the relationship between exercise and other var-
iables with IFG. After adjusting for age, gender, BMI,
smoking, LDL-C and Lp(a), only Hs-CRP, exercise time,
fasting C-peptide level, FBG, ROCK2 activity and statins
were significantly associated with IFG. After additional
adjusting for Hs-CRP, fasting C-peptide level and statins,
merely exercise time and ROCK2 activity remained sig-
nificantly associated with IFG, with odd ratio (OR) of
0.836 (active group versus controlled group, 95 % CI
0.825–0.852, p < 0.05) in exercise time, and 1.043 (con-
trolled group versus active group, 95 % CI 1.021–1.069,
p < 0.05) in ROCK2 activity.
Relationship between exercise and other variables with
ROCK2 activity
Multivariate regression analyses were performed to
evaluate the relationship between exercise and other var-
iables with ROCK2 activity. After adjusting for age, gen-
der, BMI, smoking, LDL-C and Lp(a), only Hs-CRP,
exercise time, FBG, and statins were significantly associ-
ated with ROCK2 activity. After additional adjusting for
Hs-CRP and FBG, only exercise time remained signifi-
cantly associated with ROCK2 activity, with OR of 0.822
(active group versus controlled group, 95 % CI 0.818–
0.843, p < 0.05).
Discussion
Diabetes mellitus imposes great economic and medical
burden worldwide, and preventing the pre-diabetics pro-
gressing into overt DM is beneficial to reduce the inci-
dence of DM and its associated complications such as
ASCVD. Data from our preliminary research indicates
that in subjects with IFG, 3 months of moderate aerobic
exercise is beneficial for improving fasting glucose me-
tabolism. In addition, other key variables including
serum level of Hs-CRP and ROCK2 activity were also
significantly decreased. Multivariate regression analyses
revealed that exercise time and ROCK2 activity were in-
dependently associated with IFG. Moreover, exercise
time was inversely associated with ROCK2 activity.
These data suggested that increased moderate aerobic
exercise was beneficial for improving IFG, and the
mechanism might be associated with its effects on de-
creasing ROCK2 activity.
Table 2 Variable comparison between groups 3 months’
follow-up
Variables Active (n = 52) Controlled (n = 56)
Age (years) 43.7 ± 5.2 44.9 ± 6.0
Male, n (%) 28 (53.8) 31 (55.4)
BMI (kg/m2) 23.1 ± 3.5 24.2 ± 4.6
Overweight, n (%)* 5 (9.6) 10 (17.9)
Obese, n (%) 5 (9.6) 5 (8.9)
Waist circumference (cm) 81.2 ± 5.2 82.2 ± 7.6
Smoking, n (%) 18 (34.6) 18 (32.1)
Hypertension, n (%) 13 (25.0) 13 (23.2)
Dyslipidemia, n (%) 15 (28.8) 16 (28.6)
SBP (mmHg) 120.5 ± 11.7 122.4 ± 11.3
DBP (mmHg) 75.4 ± 7.8 75.1 ± 9.0
HR (bpm) 70.3 ± 8.3 73.1 ± 7.6
TG (mmol/L) 1.6 ± 0.3 1.8 ± 0.3
TC (mmol/L) 5.1 ± 0.5 5.5 ± 0.4
LDL-C (mmol/L) 3.2 ± 0.3 3.4 ± 0.4
HDL-C (mmol/L) 1.2 ± 0.2 1.1 ± 0.3
Lp(a) (mg/L)* 109.6 ± 10.7 121.3 ± 12.4
FBG (mmol/L) 6.0 ± 0.3 6.3 ± 0.5
HbA1c (%) 5.4 ± 0.4 5.6 ± 0.3
Cr (μmol/L) 95.4 ± 10.3 99.7 ± 9.2
BUN (mmol/L) 5.7 ± 1.1 5.9 ± 1.0
Hs-CRP (mg/L)* 3.4 ± 0.7 4.9 ± 1.1
ROCK2 activity (mg/mL)* 40.6 ± 5.3 53.3 ± 7.0
Fasting C-peptide level (nmol/L)* 0.89 ± 0.11 0.46 ± 0.10
Fasting insulin level (pmol/L)* 24.3 ± 4.6 19.7 ± 3.0
Aspirin, n (%) 29 (55.8) 30 (53.7)
ACEI, n (%) 10 (19.2) 9 (16.1)
ARB, n (%) 4 (7.7) 6 (10.7)
CCB, n (%) 5 (9.6) 4 (7.1)
Statins, n (%) 16 (30.8) 17 (30.4)
IFG, n (%)* 40 (76.9) 46 (82.1)
*p < 0.05
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Accordingly, in subjects with IFG, the risk to develop
overt DM is profoundly higher than those without IFG.
Mechanically, in subjects with IFG, basic insulin produc-
tion is significantly reduced and thereby leads to fasting
blood glucose elevation. Increased serum glucose level is
detrimental to vascular wall and could result in systemic
inflammation and oxidation [7, 19]. As reflected in our
present research, serum level of Hs-CRP at baseline was
profoundly increased which is consistent with previous
reports [19, 20]. However, whether increased ROCK2 ac-
tivity is associated with the incidence of IFG, and in
addition whether exercise is useful for decreasing
ROCK2 activity has not been fully investigated yet.
Briefly, ROCK2 is an isoform of rho-associated kinase
and is expressed in multiple tissues such as vascular wall
and myocardium. Previously, many experimental studies
have revealed that increased ROCK2 activity is associ-
ated with pathogenesis of cardiovascular diseases. Inhi-
biting ROCK2 activity by its inhibitor or cardiac-specific
deletion of ROCK2 leads to profound cardio-protective
effects including reduced cardiac fibrosis and diminished
lipid accumulation in vascular wall [21, 22]. However,
whether ROCK2 activity is associated with glucose me-
tabolism is unknown yet. Our present cross-sectional re-
search revealed that in subjects with IFG, 3 months of
moderate aerobic exercise not only reduced the inci-
dence of IFG, but also attenuated ROCK2 activity. Re-
sults from multivariate regression analyses indicated that
through diminishing ROCK2 activity, exercise time im-
proved fasting blood glucose metabolism in subjects
with IFG. On the basis of pathophysiological functions
of ROCK2, we considered that the following explana-
tions might account for our findings. In the first place, it
has been reported that increased ROCK activity is asso-
ciated with phosphorylation of insulin receptor
substrate-1 (IRS-1) which thereby causes insulin resist-
ance and blood glucose elevation [23]. Secondly, since
adipocytes are the key organ in keeping glucose homeo-
stasis, and increased ROCK activity promotes inflamma-
tion and oxidation within adipocytes which thereby
negatively affects glucose metabolism [24]. Indeed, in
animal model, using ROCK inhibitor could result in im-
provement of glucose metabolism [25]. Last but not the
least, increased ROCK activity is associated with BMI,
waist circumference, and Hs-CRP level [26]. This sug-
gests that increased ROCK activity could serve as a crit-
ical contributor for DM and metabolic syndrome
development.
Another important finding of our present research was
that exercise time is negatively associated with ROCK2
activity. On the basis of the physiological roles of exer-
cise, we considered that the following mechanisms could
be used to explain this relationship. On the first hand,
exercise is beneficial for improving endothelial function
and reducing oxidative stress [27], both of which were
beneficial for attenuating ROCK2 activity. On the other
hand, since ROCK activation is dependent on small
GTP-binding protein Rho isoprenylation during choles-
terol biosynthesis. Therefore, cholesterol metabolism im-
proved by exercise might diminish Rho isoprenylation
and its associated ROCK activation. Indeed, lipid profiles
in both groups were improved after 3 months’ follow-up
in our present research, and the benefits presented in an
exercise-time dependent fashion.
Other than ROCK2 activity and IFG, other variables
including lipid profiles, fasting C-peptide and insulin,
and Hs-CRP levels were all improved in both groups
compared to the baseline. And these benefits associated
with the duration of daily average exercise time. Notably,
although data from our present research indicates a rela-
tionship between exercise time and IFG, and the under-
lying mechanism may be associated with exercise effects
on attenuating ROCK2 activity. However, we could not
draw a causal relationship owing to the inherent defect
of cross-sectional research. Rather, data from our
present research could be used as a tool for hypothesis
generation for future research.
Lastly, in our present research, we used the American
Diabetes Association criterion to define IFG (plasma
glucose levels 5.6–6.9 mmol/L) which is different from
that of World Health Organization (WHO, 6.1 mmol/L
as the cut-off value). Therefore, it is cautious to interpret
our finding when using different diagnostic criterion.
Additionally, the cut-off value to diagnose IFG in our
present research was 5.6–6.9 mmol/L, therefore, we con-
sidered that finding regarding the positive relationship
between ROCK2 activity and IFG might be applied to
wider range of population than using WHO criterion.
Moreover, since it was reported that IFG was predomin-
antly related to genetic factors, while impaired glucose tol-
erance (IGT) was predominantly related to physical
inactivity [28]. Therefore, it was possible that moderate
aerobic exercise might also improve IGT in participants
with IFG and ROCK2 activity might also be significantly
associated with IGT which deserved further investigation.
Conclusion
Our present research shows that in subjects with IFG,
increased daily average exercise time is beneficial for im-
proving fasting blood glucose metabolism, and the
mechanism operating in this process may be associated
with its effects on attenuating ROCK2 activity.
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